Mechanism of action
Azelaic acid is a saturated nine-carbon dicarboxylic acid with multiple mechanisms contributing to its therapeutic effects.
Antibacterial activity: Azelaic acid inhibits protein synthesis in Cutibacterium acnes (formerly Propionibacterium acnes) by interfering with mitochondrial oxidoreductases and DNA synthesis. This reduces the bacterial load in pilosebaceous follicles, decreasing inflammatory mediators.
Comedolytic and keratolytic effects: The drug normalizes follicular keratinization by reducing the thickness of the stratum corneum and decreasing microcomedone formation. It does not affect normal keratinocyte differentiation but selectively targets abnormal hyperkeratinization.
Anti-inflammatory properties: Azelaic acid reduces production of reactive oxygen species and decreases release of inflammatory cytokines and chemokines from neutrophils and keratinocytes. It inhibits the kallikrein-5 protease, which is upregulated in rosacea.
Depigmenting action: Azelaic acid is a competitive inhibitor of tyrosinase, the rate-limiting enzyme in melanin synthesis. This effect is selective for hyperactive melanocytes, making it useful for treating melasma and post-inflammatory hyperpigmentation without causing widespread depigmentation. The mechanism involves interference with mitochondrial respiration in abnormal melanocytes.
Unlike many topical retinoids, azelaic acid does not cause photosensitivity and can be used during daytime.
- Azelaic acid inhibits tyrosinase, making it effective for both acne and post-inflammatory hyperpigmentation.
- Pregnancy category B; first-line topical agent for acne and melasma in pregnancy when retinoids are contraindicated.
- Mechanism involves antibacterial effect on Cutibacterium acnes, normalization of keratinization, and anti-inflammatory action.
- Does NOT cause photosensitivity, unlike tretinoin; can be applied during daytime.
- FDA-approved for acne vulgaris and papulopustular rosacea; works in rosacea by inhibiting kallikrein-5.
- Most common side effect is local burning and stinging, especially in first 2-4 weeks; usually subsides with continued use.
- Minimal systemic absorption (3-5%); no systemic side effects or drug interactions.
- Can be combined with benzoyl peroxide or topical antibiotics; use caution with retinoids due to additive irritation.
Indications
Azelaic acid is FDA-approved for topical treatment of:
Acne vulgaris: Effective for mild to moderate inflammatory and comedonal acne. Particularly useful when patients cannot tolerate retinoids or benzoyl peroxide. Can be used as monotherapy or in combination regimens.
Rosacea: Approved for papulopustular (subtype 2) rosacea. Reduces inflammatory papules and pustules by targeting kallikrein-5 and cathelicidin-mediated inflammation. Does not significantly improve telangiectasias or persistent erythema.
Off-label uses include:
- Melasma: Reduces epidermal hyperpigmentation by inhibiting tyrosinase. Often combined with hydroquinone, tretinoin, or topical corticosteroids in triple-combination therapy.
- Post-inflammatory hyperpigmentation: Particularly after acne, effective in darker skin types (Fitzpatrick IV-VI) with lower risk of irritation-induced hyperpigmentation compared to hydroquinone.
- Keratosis pilaris: Keratolytic properties help reduce follicular plugging.
- Seborrheic dermatitis: Antifungal activity against Malassezia species.
Azelaic acid is pregnancy category B (safe in animal studies), making it a preferred option for acne and melasma during pregnancy when retinoids are contraindicated.
Pharmacokinetics
Absorption: Azelaic acid is formulated as a gel, cream, or foam for topical application. Percutaneous absorption is low—approximately 3-5% of the applied dose penetrates into the epidermis and dermis. Systemic absorption is minimal.
Distribution: The drug remains primarily in the epidermis and upper dermis at the site of application. Negligible amounts reach systemic circulation, and there is no significant plasma accumulation with repeated use.
Metabolism: Azelaic acid is a naturally occurring compound formed by oxidation of oleic acid by Malassezia species on normal skin. Endogenous azelaic acid is metabolized via beta-oxidation in the liver and mitochondria of various tissues. Systemically absorbed exogenous azelaic acid follows the same pathway.
Excretion: Metabolites are primarily excreted renally as shorter-chain dicarboxylic acids and carbon dioxide via respiration. The elimination half-life is approximately 12 hours for the small fraction that enters systemic circulation, but this is clinically irrelevant given minimal absorption.
Special populations: No dose adjustment is required for renal or hepatic impairment due to negligible systemic exposure. Safe in pregnancy (category B) and considered compatible with breastfeeding since systemic absorption is minimal.
Adverse effects
Azelaic acid is generally well tolerated with primarily local side effects.
Common (>5%):
- Local irritation: Burning, stinging, or tingling at application site, especially during the first 2-4 weeks. Occurs in 20-30% of patients but usually decreases with continued use.
- Erythema and dryness: Mild to moderate, typically transient.
- Pruritus: Itching at application site.
- Skin peeling or flaking: Due to keratolytic effect.
Uncommon (1-5%):
- Contact dermatitis: Allergic or irritant contact dermatitis, which may vary by formulation.
- Hypopigmentation: Rare, usually mild and reversible. Primarily affects areas of prior hyperpigmentation rather than normal skin.
- Skin rash or eczema exacerbation.
Rare (<1%):
- Severe allergic reactions: Angioedema, urticaria (extremely rare).
- Photosensitivity: Despite being safe for daytime use, occasional cases reported.
Ocular effects: If accidentally applied near eyes, may cause irritation, lacrimation, or conjunctivitis. Advise avoiding periocular area.
Systemic effects: Not observed due to minimal systemic absorption.
Management of irritation: Start with once-daily application, gradually increase to twice daily as tolerated. Apply to dry skin and use gentle cleansers. Consider temporarily reducing frequency or using emollients if irritation occurs. Gel formulations are generally better tolerated than cream formulations.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity: Known allergy to azelaic acid or any formulation component.
Warnings and precautions:
Skin irritation: Patients with sensitive skin, eczema, or compromised skin barrier may experience increased irritation. Avoid use on broken or inflamed skin until healed. Discontinue if severe irritation, hypersensitivity, or allergic reaction occurs.
Hypopigmentation risk: Although azelaic acid selectively targets hyperactive melanocytes, monitor patients with darker skin tones (Fitzpatrick IV-VI) for vitiligo-like depigmentation, particularly with prolonged use. This is rare but more common than with other depigmenting agents.
Ocular exposure: Avoid contact with eyes, mouth, and mucous membranes. If accidental exposure occurs, rinse thoroughly with water. Do not apply inside the nose or on open wounds.
Asthma history: Foam formulations contain propellants that may rarely exacerbate reactive airway disease. Use with caution in patients with severe asthma.
Pregnancy and lactation: Pregnancy category B—animal studies show no fetal harm, but human data are limited. Generally considered safe given minimal systemic absorption. Can be used during pregnancy when benefits outweigh risks, particularly for acne when retinoids are contraindicated. Compatible with breastfeeding; avoid application on breast tissue or wash thoroughly before nursing.
Pediatric use: Safety and efficacy established in patients 12 years and older for acne. Limited data in younger children.
Drug interactions: See next section for details on potential topical interactions.
Drug interactions
Azelaic acid has minimal systemic drug interactions due to negligible absorption. Interactions are primarily topical.
Potentiation of irritation:
- Topical retinoids (tretinoin, adapalene, tazarotene): Concurrent use may increase dryness, erythema, and peeling. Can be used together but consider alternating application times (e.g., retinoid at night, azelaic acid in morning) or introduce sequentially with monitoring.
- Benzoyl peroxide: Mild increase in irritation, but combination is generally well tolerated and may enhance acne efficacy.
- Alpha-hydroxy acids and salicylic acid: Additive keratolytic and irritant effects. Monitor for excessive drying.
- Alcohol-based products: Astringents, toners, and aftershaves containing alcohol may exacerbate irritation.
Depigmenting combinations:
- Hydroquinone: Often combined in melasma treatment. No pharmacokinetic interaction; may have synergistic depigmenting effect.
- Topical corticosteroids: Used in triple-combination therapy (hydroquinone + tretinoin + steroid). Azelaic acid can be substituted or added; no interaction.
No significant interactions with:
- Systemic antibiotics (including tetracyclines)
- Oral contraceptives
- Systemic retinoids (isotretinoin)
- Topical or systemic antifungals
Clinical approach: When combining multiple topical agents, introduce azelaic acid gradually. Apply moisturizer and sunscreen as the final layer. Space applications by 10-15 minutes if applying multiple products at the same time. Consider alternating use (morning vs. evening) if irritation occurs.
No food or alcohol interactions exist given the topical route and minimal systemic absorption.
Clinical pearls
Practical prescribing:
- Start slow: Begin with once-daily application (evening) for 1-2 weeks, then advance to twice daily as tolerated. This minimizes initial irritation and improves adherence.
- Application technique: Apply thin layer to clean, dry skin. Washing face and waiting 5-10 minutes before application reduces stinging. Avoid occlusive dressings.
- Time to effect: Improvement in acne typically seen in 4-6 weeks; melasma and post-inflammatory hyperpigmentation may require 12-24 weeks for optimal results. Counsel patients on realistic timelines to maintain adherence.
- Combination therapy: Azelaic acid pairs well with topical antibiotics (clindamycin, erythromycin) for acne. Safe with most other acne and rosacea treatments when introduced gradually.
Exam-relevant distinctions:
- Pregnancy-safe acne option: Unlike tretinoin (category C/X), azelaic acid is category B and a first-line choice for pregnant patients with acne or melasma.
- Does not cause photosensitivity: Unlike retinoids, can be applied in morning without increased sunburn risk—but sunscreen still recommended for melasma.
- Dual mechanism: Unique among topical acne agents in providing both antibacterial/anti-inflammatory effects and depigmenting action, making it ideal for post-inflammatory hyperpigmentation in acne patients.
- Selective tyrosinase inhibition: Targets hyperactive melanocytes preferentially, unlike hydroquinone which affects all melanocytes more uniformly.
Rosacea advantage: One of few FDA-approved topical treatments for papulopustular rosacea. Targets kallikrein-5, the enzyme implicated in rosacea pathophysiology, unlike antibiotics which work via anti-inflammatory effects alone.
Cost and formulation considerations: Gel and foam formulations are usually better tolerated than cream formulations (less greasy, fewer excipients). Foam dries quickly and works well for oily skin. Generic formulations available.
Monitoring: No laboratory monitoring required. Assess for therapeutic response at 6-12 weeks for acne, 12-24 weeks for pigmentation disorders. Watch for worsening hypopigmentation in dark-skinned patients.
Patient counseling: Warn about initial burning/stinging that typically resolves. Emphasize sunscreen use for melasma. Safe to use with makeup once dried.
Practice questions
1. A 28-year-old pregnant woman at 14 weeks gestation presents with worsening facial acne and asks for treatment. She was using topical tretinoin before pregnancy but discontinued it upon learning she was pregnant. Physical examination shows moderate inflammatory papules and comedones on her cheeks and forehead, with scattered areas of post-inflammatory hyperpigmentation. Which of the following is the most appropriate topical agent for this patient?
2. A 35-year-old woman with rosacea has been using topical metronidazole for 8 weeks with minimal improvement. She continues to have multiple erythematous papules and pustules on her nose and cheeks but no telangiectasias. Her dermatologist decides to add a second topical agent that works by inhibiting kallikrein-5 protease. Which of the following is the mechanism by which this additional agent will benefit her rosacea?
3. A 42-year-old woman with melasma has been applying azelaic acid cream twice daily for 4 weeks without improvement. She asks why the medication has not worked yet. In addition to counseling about realistic treatment timelines, which of the following properties of azelaic acid best explains its mechanism of action in treating melasma?
Frequently asked questions
How does azelaic acid work for acne?
Azelaic acid works through multiple mechanisms: it inhibits bacterial protein synthesis in Cutibacterium acnes, normalizes follicular keratinization to prevent comedone formation, reduces inflammatory cytokine production, and inhibits tyrosinase to lighten post-inflammatory hyperpigmentation. These combined effects make it effective for both inflammatory and comedonal acne while also addressing the dark marks that often follow acne lesions, particularly in patients with darker skin tones.
What are the side effects of azelaic acid?
The most common side effects are local skin reactions including burning, stinging, or tingling (20-30% of users), especially during the first few weeks of use. Other effects include redness, dryness, itching, and mild peeling. These reactions typically decrease with continued use. Serious side effects are rare but can include contact dermatitis or, very rarely, hypopigmentation in areas of application. Systemic side effects do not occur because absorption through the skin is minimal (only 3-5%).
Is azelaic acid safe during pregnancy?
Yes, azelaic acid is pregnancy category B and is considered safe for use during pregnancy. Animal studies have shown no fetal harm, and systemic absorption is minimal (3-5%) with topical use, meaning very little drug enters the bloodstream. It is a preferred treatment option for acne, melasma, and hyperpigmentation in pregnant women, especially since retinoids (like tretinoin) are contraindicated during pregnancy due to teratogenic risk. It is also considered compatible with breastfeeding.
Azelaic acid vs hydroquinone — what is the difference?
Both are depigmenting agents that inhibit tyrosinase, but they differ in selectivity and safety profile. Azelaic acid preferentially targets hyperactive melanocytes while sparing normal melanocytes, reducing the risk of widespread depigmentation. It is pregnancy category B and has minimal systemic absorption. Hydroquinone is a more potent tyrosinase inhibitor but affects all melanocytes more uniformly and carries risks of ochronosis (blue-black darkening) with prolonged use, contact dermatitis, and is contraindicated in pregnancy. Azelaic acid also has antibacterial and anti-inflammatory properties that hydroquinone lacks.
Can you use azelaic acid with retinol or tretinoin?
Yes, but with caution due to potential for increased irritation. Both azelaic acid and retinoids (retinol, tretinoin) have keratolytic effects, so using them together can cause excessive dryness, redness, and peeling. The safest approach is to alternate application times—for example, applying tretinoin at night and azelaic acid in the morning—or to introduce them sequentially, starting with one agent and adding the second after several weeks of tolerance. Some patients can use both simultaneously with proper moisturization, but this requires monitoring for irritation.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: D10AX03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.